Figure 1 | Scientific Reports

Figure 1

From: The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats

Figure 1

Study design and treatment groups. Riociguat or vehicle were gavaged once daily for 2–3 weeks to rats in early and advanced stages of cholestatic (BDL) or toxic (CCl4) cirrhosis, and to respective controls. Subsequently, portal and systemic hemodynamics were assessed and the degree of liver fibrosis quantified. The PPVL model was used to study hemodynamic effects in non-cirrhotic prehepatic portal hypertension.

Back to article page